Current Report Filing (8-k)
August 04 2016 - 12:53PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 4, 2016
ALBANY MOLECULAR RESEARCH, INC.
(Exact Name of Registrant as Specified in
Charter)
Delaware
|
001-35622
|
14-1742717
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
26 Corporate Circle Albany, NY
|
12212
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(518) 512-2000
(Former name or
former address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(
see
General Instruction A.2. below) :
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02 Results of Operations
and Financial Condition
On August 4, 2016, Albany Molecular Research, Inc.
(the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2016.
That release referred to certain attached financial highlights for the second quarter ended June 30, 2016. The full text
of the press release, including the financial tables referred to within the release, which were posted on the Company’s internet
website, is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.
Item 9.01 Financial Statements
and Exhibits
|
(d)
|
Exhibits
|
|
|
|
|
|
|
99.1
|
Press release and financial tables dated August 4, 2016, issued by Albany Molecular Research, Inc.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 4, 2016
|
ALBANY MOLECULAR RESEARCH, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Felicia Ladin
|
|
|
Name:
|
Felicia Ladin
|
|
|
Title:
|
Senior Vice President, Chief Financial Officer and Treasurer
|
Albany Molecular Research, Inc. (NASDAQ:AMRI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Albany Molecular Research, Inc. (NASDAQ:AMRI)
Historical Stock Chart
From Apr 2023 to Apr 2024